Microvascular Dysfunction in Obesity
Impaired endothelial function is observed in disease states related to obesity, such as atherosclerosis, coronary artery disease, and diabetes. Reactive oxygen species (ROS) production and resultant oxidative stress contribute to the development of these obesity-related diseases. The enzyme NADPH-oxidase is a major sou
| Condition(s) | Obesity, Endothelial Dysfunction |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Impaired endothelial function is observed in disease states related to obesity, such as atherosclerosis, coronary artery disease, and diabetes. Reactive oxygen species (ROS) production and resultant oxidative stress contribute to the development of these obesity-related diseases. The enzyme NADPH-oxidase is a major source of oxidative stress within the vasculature, and has been linked with the Metabolic Syndrome. In the investigator's previously funded studies, the investigators demonstrated for the first time that: 1) in vivo ROS were elevated in skeletal muscle of obese as compared to lean or overweight human subjects, 2) perfusion of the NADPH-oxidase inhibitor apocynin locally into muscle normalized ROS levels and reversed local microvascular endothelial dysfunction in the obese indivi |
| Who can participate | Inclusion Criteria: * There will be no restrictions with regard to race, sex, or socioeconomic status. * Women will be premenopausal * Women will be on combined estrogen/progestin hormonal contraceptive therapy (oral pill, transdermal patch or vaginal ring). * Sedentary obese individuals will have been weight stable for the preceding 6 months. * Sedentary obese individuals will have the Metabolic Syndrome as defined according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). * Individuals with the Metabolic Syndrome will have at least three of the following: 1. Central obesity as measured by waist circumference (men \>40 inches; women \>35 inches); 2. Fastin |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Florida State University |
| Locations | Tallahassee, Florida, United States |
| Start date | 2019-11-20 |
| NCT ID | NCT04087655 |
| Official listing | https://clinicaltrials.gov/study/NCT04087655 |